...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Could Xuebijing Injection Reduce the Mortality of Severe Pneumonia Patients? A Systematic Review and Meta-Analysis
【24h】

Could Xuebijing Injection Reduce the Mortality of Severe Pneumonia Patients? A Systematic Review and Meta-Analysis

机译:Xuebijing注射可以降低严重肺炎患者的死亡率吗?系统审查和荟萃分析

获取原文
           

摘要

Background and Aim. Xuebijing injection (XBJ) is a Chinese traditional medicine preparation, mainly made from Carthamus tinctorius flowers (Honghua in Chinese), Paeonia lactiflora roots (Chishao), Ligusticum chuanxiong rhizomes (Chuanxiong), Salvia miltiorrhiza roots (Danshen), and Angelica sinensis roots (Danggui). It can reduce inflammation and regulate blood coagulation and immune function. XBJ has been used in severe pneumonia patients in China. Whether it can reduce the mortality of patients is still controversial. This study aimed to analyze the effectiveness of XBJ in the treatment of severe pneumonia. Methods. Databases including PubMed, Cochrane Library, Web of Science, Embase, CNKI, WanFang, and VIP were searched, from inception to February 2020, to identify randomized controlled trials (RCTs) about XBJ combined with western medicine treatment in treating severe pneumonia. Literature screening, data extraction, and methodological quality assessment were carried out by two researchers back-to-back. RevMan 5.3 software was used for statistical analysis. Results. A total of 21 articles involving 2072 patients were included. The meta-analysis showed that treatment combined with XBJ has better efficiency compared with western medicine treatment alone. It could also decrease 28-day mortality; shorten the length of intensive care unit (ICU) stay time and mechanical ventilation time; and reduce the levels of C-reactive protein (CRP), procalcitonin (PCT), white blood cell (WBC), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and D-dimer in the serum of patients. The incidence of adverse reactions did not increase significantly. Conclusion. XBJ combined with western medicine treatment has significant clinical efficacy and no obvious adverse reactions. A dose of 100?ml bid is recommended to reduce 28-day mortality. The conclusion needs to be further verified with larger-sample size and higher-quality RCTs.
机译:背景和目标。 Xuebijing注射(XBJ)是一种中国传统医药制剂,主要由Carthamus Tinctorius花(Honghua中文),Paeonia Lactiflora Roots(Chishao),Ligusticum Chuanhiong Rhizomes(川芎),丹参米尔蒂希萨罗斯(丹参),和当归的Sinensis Roots( Danggui)。它可以减少炎症并调节血液凝固和免疫功能。 XBJ已在中国的严重肺炎患者中使用。无论是否降低患者的死亡率仍然存在争议。本研究旨在分析XBJ治疗严重肺炎的有效性。方法。从20020年2月开始,研究包括PubMed,Cochrane图书馆,科学,Empase,CNKI,WANFANG和VIP的数据库,以确定关于XBJ的随机对照试验(RCT)与西药治疗治疗严重肺炎。由两位研究人员背靠背进行文献筛选,数据提取和方法论质量评估。 Revman 5.3软件用于统计分析。结果。共有21项涉及2072名患者的文章。与单独的西药治疗相比,Meta分析表明,与XBJ相结合的效率更好。它也可能降低28天的死亡率;缩短重症监护单元(ICU)停留时间和机械通气时间;并降低C反应蛋白(CRP),ProCalcitonin(PCT),白细胞(WBC),肿瘤坏死因子-α(TNF-α),白细胞介素-6(IL-6)和D-二聚体的水平患者的血清。不良反应的发生率并没有显着增加。结论。 XBJ结合西药治疗具有显着的临床疗效,无明显不良反应。建议使用100毫升的剂量来减少28天的死亡率。结论需要通过较大样本的大小和更高质量的RCT进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号